Visudyne verteporfin: QLT said it expects to complete in mid-2003 enrollment of 360 patients in its ongoing North American Phase III VIO trial of Visudyne to tr

QLT Inc. (QLTI; TSE:QLT), Vancouver, B.C.
Product: Visudyne verteporfin
Business: Ophthalmic

Read the full 110 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE